Stroma: Fertile soil for inflammation

Best Practice and Research: Clinical Rheumatology

Volumn 28, Issue 4, 2014, Pages 565-576

  Patel, Rikesh ^a   Filer, Andrew ^a   Barone, Francesca ^a   Buckley, Christopher D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Fibroblast; Inflammation; Rheumatoid arthritis; Stroma; Stromal cell; Synovium

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CXCL13 CHEMOKINE; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MATRIX METALLOPROTEINASE; P21 ACTIVATED KINASE; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; SOIL;

APOPTOSIS; B LYMPHOCYTE; CELL ACTIVATION; CELL SURVIVAL; CHRONIC INFLAMMATION; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; INFLAMMATION; JOINT DESTRUCTION; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; NONHUMAN; PERICYTE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STROMA; STROMA CELL; SYNOVIUM; T LYMPHOCYTE; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; SOIL; SYNOVITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FIBROBLASTS; HUMANS; INFLAMMATION; SOIL; STROMAL CELLS; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 84927710877     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2014.10.022     Document Type: Review

References (89)

1. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007 Feb;21(2):325-32.
2. McGettrick HM, Butler LM, Buckley CD, et al. Tissue stroma as a regulator of leukocyte recruitment in inflammation. J Leukoc Biol 2012 Mar;91(3):385-400.
3. Tailor A, Flower RJ, Perretti M. Dexamethasone inhibits leukocyte emigration in rat mesenteric post-capillary venules: an intravital microscopy study. J Leukoc Biol 1997 Sep;62(3):301-8.
4. Filer A, Raza K, Salmon M, et al. Targeting stromal cells in chronic inflammation. Discov Med 2007 Feb;7(37):20-6.
5. Phan SH. Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc 2008 Apr 15;5(3):334-7.
6. Buckley CD, Halder S, Hardie D, et al. Report on antibodies submitted to the stromal cell section of HLDA8. Cell Immunol 2005 Jul-Aug;236(1-2):29-41.
7. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006 May;6(5):392-401.
8. Chang HY, Chi JT, Dudoit S, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 2002 Oct 1;99(20):12877-82.
9. Hematti P. Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? Cytotherapy 2012 May;14(5):516-21.
10. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013 Oct 3; 13(4):392-402.
11. Komuro T. Re-evaluation of fibroblasts and fibroblast-like cells. Anat Embryol Berl 1990;182(2):103-12.
12. Rodemann HP, Muller GA. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991 Jun;17(6): 684-6.
13. Simian M, Hirai Y, Navre M, et al. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development 2001 Aug;128(16):3117-31.
14. Naylor AJ, Filer A, Buckley CD. The role of stromal cells in the persistence of chronic inflammation. Clin Exp Immunol 2013 Jan;171(1):30-5.
15. Filer A. The fibroblast as a therapeutic target in rheumatoid arthritis. Curr Opin Pharmacol 2013 Jun;13(3):413-9.
16. Barone F, Nayar S, Buckley CD. The role of non-hematopoietic stromal cells in the persistence of inflammation. Front Immunol 2012;3:416.
17. Buckley CD, Pilling D, Lord JM, et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001 Apr;22(4):199-204.
18. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002 May 10; 296(5570):1046-9.
19. Rettig WJ, Su SL, Fortunato SR, et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer 1994 Aug 1;58(3):385-92.
20. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010 Nov 5;330(6005):827-30.
21. Dolberg DS, Hollingsworth R, Hertle M, et al. Wounding and its role in RSV-mediated tumor formation. Science 1985 Nov 8;230(4726):676-8.
22. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999 May;5(5):1041-56.
23. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 2002 Oct;14(5):581-6.
24. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990 Apr;70(2):427-51.
25. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995;57:827-72.
26. Luscinskas FW, Ding H, Lichtman AH. P-selectin and vascular cell adhesion molecule 1 mediate rolling and arrest, respectively, of CD4+ T lymphocytes on tumor necrosis factor alpha-activated vascular endothelium under flow. J Exp Med 1995 Mar 1;181(3):1179-86.
27. Piali L, Weber C, LaRosa G, et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol 1998 Mar;28(3):961-72.
28. Luu NT, Rainger GE, Nash GB. Differential ability of exogenous chemotactic agents to disrupt transendothelial migration of flowing neutrophils. J Immunol 2000 Jun 1;164(11):5961-9.
29. Sheikh S, Rahman M, Gale Z, et al. Differing mechanisms of leukocyte recruitment and sensitivity to conditioning by shear stress for endothelial cells treated with tumour necrosis factor-alpha or interleukin-1beta. Br J Pharmacol 2005 Aug; 145(8):1052-61.
30. Dangerfield JP, Wang S, Nourshargh S. Blockade of alpha6 integrin inhibits IL-1beta- but not TNF-alpha-induced neutrophil transmigration in vivo. J Leukoc Biol 2005 Feb;77(2):159-65.
31. McGettrick HM, Hunter K, Moss PA, et al. Direct observations of the kinetics of migrating T cells suggest active retention by endothelial cells with continual bidirectional migration. J Leukoc Biol 2009 Jan;85(1):98-107.
32. McGettrick HM, Smith E, Filer A, et al. Fibroblasts from different sites may promote or inhibit recruitment of flowing lymphocytes by endothelial cells. Eur J Immunol 2009 Jan;39(1):113-25.
33. Filer A, Parsonage G, Smith E, et al. Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. Arthritis Rheum 2006 Jul;54(7): 2096-108.
34. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000 Nov-Dec; 13(Suppl. 3):S111-20.
35. Smith RS, Smith TJ, Blieden TM, et al. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997 Aug;151(2):317-22.
36. Zhang Y, Cao HJ, Graf B, et al. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol 1998 Feb 1;160(3):1053-7.
37. Hogaboam CM, Steinhauser ML, Chensue SW, et al. Novel roles for chemokines and fibroblasts in interstitial fibrosis. Kidney Int 1998 Dec;54(6):2152-9.
38. Pap T, Muller-Ladner U, Gay RE, et al. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000;2(5):361-7.
39. Hogaboam CM, Bone-Larson CL, Lipinski S, et al. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J Immunol 1999 Aug 15;163(4):2193-201.
40. Karouzakis E, Gay RE, Michel BA, et al. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009 Dec;60(12):3613-22.
41. Ospelt C, Reedquist KA, Gay S, et al. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? Autoimmun Rev 2011 Jul;10(9):519-24.
42. Smith E, McGettrick HM, Stone MA, et al. Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synovium. Arthritis Rheum 2008 Jul;58(7): 1968-73.
43. Lally F, Smith E, Filer A, et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum 2005 Nov;52(11):3460-9.
44. McGettrick HM, Buckley CD, Filer A, et al. Stromal cells differentially regulate neutrophil and lymphocyte recruitment through the endothelium. Immunology 2010 Nov;131(3):357-70.
45. Bradfield PF, Amft N, Vernon-Wilson E, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum 2003 Sep;48(9):2472-82.
46. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999 Aug 19;400(6746):776-80.
47. Burman A, Haworth O, Hardie DL, et al. A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol 2005 Feb 1;174(3): 1693-700.
48. Fries KM, Blieden T, Looney RJ, et al. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 1994 Sep;72(3):283-92.
49. Nishikawa SI, Hashi H, Honda K, et al. Inflammation, a prototype for organogenesis of the lymphopoietic/hematopoietic system. Curr Opin Immunol 2000 Jun;12(3):342-5.
50. Luther SA, Lopez T, BaiW, et al. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000 May;12(5):471-81.
51. Fan L, Reilly CR, Luo Y, et al. Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol 2000 Apr 15;164(8):3955-9.
52. Henry RA, Kendall PL. CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice. J Immunol 2010 Aug 1;185(3):1460-5.
53. Peduto L, Dulauroy S, Lochner M, et al. Inflammation recapitulates the ontogeny of lymphoid stromal cells. J Immunol 2009 May 1;182(9):5789-99.
54. Manzo A, Paoletti S, Carulli M, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005 May;35(5):1347-59.
55. Hjelmstrom P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukoc Biol 2001 Mar;69(3):331-9.
56. van de Sande MG, Thurlings RM, Boumans MJ, et al. Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time? Ann Rheum Dis 2011 Apr; 70(4):700-3.
57. Pilling D, Fan T, Huang D, et al. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 2009;4(10):e7475.
58. Pilling D, Akbar AN, Girdlestone J, et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol 1999 Mar;29(3):1041-50.
59. Parsonage G, Falciani F, Burman A, et al. Global gene expression profiles in fibroblasts from synovial, skin and lymphoid tissue reveals distinct cytokine and chemokine expression patterns. Thromb Haemost 2003 Oct;90(4):688-97.
60. Pablos JL, Amara A, Bouloc A, et al. Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol 1999 Nov;155(5):1577-86.
61. Agace WW, Amara A, Roberts AI, et al. Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 2000 Mar 23;10(6):325-8.
62. Nagata S, Golstein P. The fas death factor. Science 1995 Mar 10;267(5203):1449-56.
63. Orteu CH, Poulter LW, Rustin MH, et al. The role of apoptosis in the resolution of T cell-mediated cutaneous inflammation. J Immunol 1998 Aug 15;161(4):1619-29.
64. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997 Feb 1;99(3):439-46.
65. Orteu CH, Rustin MH, O'Toole E, et al. The inhibition of cutaneous T cell apoptosis may prevent resolution of inflammation in atopic eczema. Clin Exp Immunol 2000 Nov;122(2):150-6.
66. Akbar AN, Borthwick NJ, Wickremasinghe RG, et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 1996 Feb;26(2):294-9.
67. Akbar AN, Borthwick N, Salmon M, et al. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med 1993 Aug 1;178(2):427-38.
68. Okamoto H, Hoshi D, Kiire A, et al. Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets 2008 Mar; 7(1):53-66.
69. Burger JA, Zvaifler NJ, Tsukada N, et al. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cellderived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 2001 Feb;107(3):305-15.
70. Bombardieri M, Kam NW, Brentano F, et al. A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann Rheum Dis 2011 Oct; 70(10):1857-65.
71. Clark IM, Powell LK, Ramsey S, et al. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993 Mar;36(3):372-9.
72. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994 Jul 7;370(6484):61-5.
73. Grassi F, Cristino S, Toneguzzi S, et al. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 2004 May;199(2):244-51.
74. Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006;8(6):R171.
75. Huet G, Flipo RM, Richet C, et al. Measurement of elastase and cysteine proteinases in synovial fluid of patients with rheumatoid arthritis, sero-negative spondylarthropathies, and osteoarthritis. Clin Chem 1992 Sep;38(9):1694-7.
76. Trabandt A, Aicher WK, Gay RE, et al. Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/I mice and patients with rheumatoid arthritis. Matrix 1990 Dec;10(6):349-61.
77. Lemaire R, Huet G, Zerimech F, et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol 1997 Jul;36(7):735-43.
78. Gao CY, Zelenka PS. Cyclins, cyclin-dependent kinases and differentiation. Bioessays 1997 Apr;19(4):307-15.
79. Nasu K, Kohsaka H, Nonomura Y, et al. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 2000 Dec 15;165(12):7246-52.
80. Perlman H, Bradley K, Liu H, et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 2003 Jan 15;170(2):838-45.
81. Nonomura Y, Kohsaka H, Nagasaka K, et al. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol 2003 Nov 1;171(9):4913-9.
82. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002 Feb;46(2):357-65.
83. Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7(4):R784-95.
84. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988 Feb 1;167(2):332-44.
85. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a cochrane systematic review. J Rheumatol 2011 Jan;38(1):10-20.
86. Rosengren S, Corr M, Firestein GS, et al. The JAK inhibitor CP-690, 550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012 Mar;71(3):440-7.
87. Kiener HP, Niederreiter B, Lee DM, et al. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis Rheum 2009 May;60(5):1305-10.
88. Maia M, de Vriese A, Janssens T, et al. CD248 and its cytoplasmic domain: a therapeutic target for arthritis. Arthritis Rheum 2010 Dec;62(12):3595-606.
89. Matthys P, Hatse S, Vermeire K, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001 Oct 15;167(8):4686-92.